PBLS at a glance
Parabilis Medicines Inc (PBLS, SEC CIK 1657677) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Parabilis Medicines Inc (PBLS) shares worth $627.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on July 22, 2026 of 47,250 shares at $29.77 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $627.8M · +8 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added regulatory risk: June 2026 FDA draft guidance may require additional evidence despite single-trial pathway
- Most material clinical update: March 2026 injectable formulation paused after Grade 1 and Grade 2 injection-site reactions
- AI compliance risk: EU Artificial Intelligence Act obligations became effective August 2, 2026
- Operational risk: Alcami remains the sole drug-product supplier
- Financial risk: $1,072.9 million cash, cash equivalents and marketable securities funding operations into 2030
Management Discussion & Analysis
- Quarterly revenue $2.1M vs $0, including $0.7M Regeneron and $1.4M Altos collaboration revenue
- Net loss $44.5M vs $33.5M, operating expenses $56.9M vs $34.8M
- R&D highest spender: zolucatetide $17.8M, up 118.9% YoY; ERG degrader $1.2M, down 16.1%
- Cash, equivalents and marketable securities $1,072.9M, funding operations into 2030
- IPO and private placement generated $787.9M net; Regeneron upfront payment $50.0M
- Near-term outlook: Phase 3 zolucatetide trial planned for first half 2027; substantial additional funding required
AI summary of the PBLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced
- Press release includes Parabilis Medicines’ financial results and business highlights
Item EX-99.1: Item EX-99.1
- Zolucatetide desmoid-tumor data: 72.2% ORR at 32 weeks, 100% DCR across 46 patients, with no treatment-related discontinuations
- FDA-aligned PEDESTAL Phase 3 design, planned launch in first half 2027 and topline results anticipated in 2029
Item 1.01: Entry into a Material Definitive Agreement
- Headquarters footprint expands by 33,525 square feet at 20 Acorn Park Drive beginning January 1, 2028
- Rent on added space starts January 1, 2029, deferring cash outflows for one year
Item 7.01: Regulation FD Disclosure
- Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026
- Data concern patients with desmoid tumors, a key clinical development milestone
AI summaries of PBLS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PBLS
Don't miss the next PBLS filing
- Alerts as it files. A push when PBLS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PBLS, by share count.
- Ask anything. An AI agent that reads every PBLS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Tendler Craig | A | Aug 22, 2026 | 20,294 | - |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 22, 2026 | 47,250 | $29.77 |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 21, 2026 | 37,723 | $30.00 |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 21, 2026 | 21,696 | $27.96 |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 21, 2026 | 6,504 | $29.17 |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 20, 2026 | 32,987 | $27.72 |
| RA CAPITAL MANAGEMENT, L.P. | Buy | Jul 20, 2026 | 98,433 | $27.13 |
| SEBULSKY ALAN | Buy | Jun 15, 2026 | 5,000 | $26.00 |
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PBLS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $627.8M |
| Q2 2026 | 16 | $664.5M |
- Goldman Sachs Group+594.2K (+7200%)
- Vanguard Capital Management LLC+399.3K (+35%)
- Vanguard Portfolio Management LLC+280.0K (+21%)
- Franklin Resources+67.7K (+18%)
- Two Sigma Investments+58.3K (+667%)
- Ameriprise Financial−23.9K (-14%)
- BlackRock+2.79M
- State Street Corp+757.8K
- Northern Trust+298.3K
- Bank of America Corp+103.5K
- BNY Mellon+102.4K
- FMR LLC (Fidelity)−10.29M
Source: 13F-HR filings on SEC EDGAR (aggregated from 40 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PBLS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PBLS SEC filings: frequently asked questions
Which institutions hold PBLS stock?
As of September 30, 2026, the largest Parabilis Medicines Inc (PBLS) holders among the 13F filers tracked by SignalX were Alphabet Inc ($158.9 million), Regeneron Pharmaceuticals ($134.5 million), BlackRock ($90.1 million), Vanguard Portfolio Management LLC ($51.1 million), Vanguard Capital Management LLC ($50.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did PBLS report in its latest 8-K?
Parabilis Medicines Inc (PBLS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced.
What are the latest PBLS SEC filings?
Parabilis Medicines Inc (PBLS) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 25, 2026.
What is PBLS's SEC CIK number?
Parabilis Medicines Inc (PBLS)'s SEC Central Index Key (CIK) is 1657677. EDGAR lists every PBLS filing under that number.
Ask anything about PBLS
The research agent reads PBLS's filings, financials, insider trades and 13F holders, then answers with sources.